Educational Grants

Educational Grants is sponsored by Organon. Supports independent medical educational activities in women's health, including menstrual health education for healthcare professionals.

Educational Grants - Organon Grants Our goal is to support high-quality education focused on creating a better, healthier every day for families and communities. Organon accepts requests for Grants for Education to fund independent medical educational (IME) activities that are high-quality, unbiased, and evidence-based.

Educational activities may be accredited and non-accredited and in the field of: We are motivated by a woman’s evolving health needs throughout her lifetime. That’s why our intention is to take on some of the issues that matter most to her. This includes supporting education for healthcare professionals.

Our therapeutic areas of interest are: We prioritize our patients first through listening, learning, and understanding their needs. Organon provides monetary IME Grants to support evidence-based education to improve healthcare professionals’ knowledge, skills, competence and/or professional performance. This will help to enable better patient care and overall enhancement of the healthcare system.

Our therapeutic areas of interest are: Consideration requirements Our Company supports IME initiatives grounded in learning, data, behavioral, and implementation sciences. Grant funding can only be provided to eligible organizations and not to individual healthcare professionals.

Eligible organizations may include hospitals, academic medical centers, medical schools, professional medical associations/societies, and medical education companies.

In order to be considered, each request to support an independent medical education grant must: be unsolicited and independent of Organon influence seek to close an identified educational gap a therapeutic area or area of interest that Organon focuses on meet set eligibility criteria be submitted a minimum of 60 days prior to the activity start date, and provide a post activity financial reconciliation and outcomes measurements IME Grant funding may not be made directly or indirectly to, or for the benefit of, an individual person or persons, and not to a privately owned ‘for profit’ entity.

What does not fall in the IME Grant definition: Investigator Studies Program Submission of a proposal does not imply or guarantee approval. All decisions regarding funding are made at the discretion of Organon. This site is intended for US only.

Requests for IME grants outside of the US should contact their local Organon office. You are leaving Organon. com Forward-looking statement of Organon This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful.

If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www. sec. gov Opens a new window ).

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.